RE:Not one, but two positive news items out today Canadafan, whilst news of efficacy is always welcome, it is not the news the investment community is waiting for. They want to know that ONCY has funding to see any phase III through to submission. Pre-market isn't exactly suggesting anything different.
The company as far I recall has now been claiming for around 10 years that it is in discussions with partners. But nothing ever matierializes. UNTIL they have conclusive statistical data that Pela + Combo improves on the current standard of care, the PPS is going nowhere but down as they burn through cash.
It's way beyond time for ONCYto either put up or shut up. Enough of the dog and pony show, investors want a trial, adequately financed, adequately monitored (patients with mild fever not being removed from the trials unnecessarily) and adequately powered to show statistically relevant end points.
One very positive takeaway was : A correlation between the expansion in the blood of TIL-specific clones and tumor response.
I hope that will enable some meaningful chance of an accelerated approval pathway...
But pre-market doesn't seem to value this data one jot.... so, now we wait till Q3 results call